Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Multicenter Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7296682, A CD25-Targeting, T-Regulatory Cell Depleting Antibody in Participants With Advanced and/or Metastatic Solid Tumor

Next Previous
Trial Profile

An Open-Label, Multicenter Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7296682, A CD25-Targeting, T-Regulatory Cell Depleting Antibody in Participants With Advanced and/or Metastatic Solid Tumor

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 07 Mar 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vopikitug (Primary)
  • Indications Carcinoma; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer
  • Focus Adverse reactions; First in man
  • Sponsors Roche

Most Recent Events

  • 19 Apr 2023 Results from NCT04158583 and NCT04642365; assessing PK/PD analysis presented at the 114th Annual Meeting of the American Association for Cancer Research
  • 19 Apr 2023 Results from NCT04158583 and NCT04642365; assessing Safety and anti-tumor activity , presented at the 114th Annual Meeting of the American Association for Cancer Research
  • 31 Mar 2023 According to a iBio Inc media release, the company look forward to anticipated presentation of clinical data at the 2023 American Association for Cancer Research Annual Meeting in April.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top